Does industry-conducted all-case surveillance of newly approved oncology drugs contribute to revision of package inserts in Japan?
|アブストラクト||In Japan, the Pharmaceuticals and Medical Devices Agency (PMDA) requires all-case surveillance studies (ACSS) for many novel oncology drugs as a condition for approval. However, this is a major burden on the pharmaceutical industry and clinicians. The objective of this analysis was to investigate whether ACSS can contribute essential new information on severe adverse drug reactions (ADRs), which are necessary to revise package inserts of drugs. All oncology drugs for which ACSS were required from January 2006 to September 2015 found on the PMDA website were reviewed, and the influence of ACSS on the package insert content was evaluated. Most of the package insert revisions regarding serious treatment-related AEs were based on spontaneous reports from clinicians. The contribution of ACSS results to the revision of package inserts is limited, and comes at the cost of huge financial resources and labor. An alternative, more efficient adverse event reporting system is necessary. This article is protected by copyright. All rights reserved.|
|投稿者||Suzuki, Akiyuki; Sato, Hitoshi; Sasaki, Yasutsuna|
|ジャーナル名||Clinical and translational science|
|組織名||Division of Pharmacokinetics and Pharmacodynamics, Department of Drug;Information, Showa University School of Pharmacy, Tokyo, Japan.;Division of Medical Oncology, Department of Medicine, Showa University School of;Medicine, Tokyo, Japan.;Oncology Center, Musashino Tokushukai Hospital, Tokyo, Japan.|